Pigment Epithelium-Derived Factor (PEDF) prevents Advanced Glycation End products (AGEs)-elicited endothelial Nitric Oxide Synthase (eNOS) reduction through its anti-oxidative properties

Protein and Peptide Letters

Volumn 14, Issue 8, 2007, Pages 832-835

  Yamagishi, Sho Ichi ^a   Ueda, Seiji ^a   Matsui, Takanori ^a   Nakamura, Kazuo ^a   Imaizumi, Tsutomu ^a   Takeuchi, Masayoshi ^b   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; eNOS; Oxidative stress; PEDF; Peroxynitrite

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EYE PROTEIN; NERVE GROWTH FACTOR; NOS3 PROTEIN, HUMAN; PIGMENT EPITHELIUM DERIVED FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; REACTIVE OXYGEN METABOLITE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; HUMAN; METABOLISM; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; EYE PROTEINS; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NERVE GROWTH FACTORS; NITRIC OXIDE SYNTHASE TYPE III; REACTIVE OXYGEN SPECIES; SERPINS;

EID: 34548679360     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986607781483705     Document Type: Article

References (26)

1. Tombran-Tink, J., Chader, C.G., and Johnson, L.V. (1991) PEDF: Pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res., 53, 411-414.
2. Dawson, D.W., Volpert, O.V., Gillis, P., Crawford, S.E., Xu, H.J., Benedict, W., and Bouck, N.P. (1999) Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science, 285, 245-248.
3. Duh, E.J., Yang, H.S., Suzuma, I., Miyagi, M., Youngman, E., Mori, K., Katai, M., Yan, L., Suzuma, K., West, K., Davarya, S., Tong, P., Gehlbach, P., Pearlman, J., Crabb, J.W., Aiello, L.P., Campochiaro, P.A., and Zack, D.J. (2002) Pigment epitheliumderived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci., 43, 821-829.
4. Yamagishi, S., Nakamura, K., Matsu, T., Yoshida, T., Takeuchi, M., and Imaizumi T. (2007) Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm. Metab. Res., 39, 233-235.
5. Spranger, J., Osterhoff, M., Reimann, M., Mohlig, M., Ristow, M., Francis, M.K., Cristofalo, V., Hammes, H.P., Smith, G., Boulton, M., Pfeiffer, F.H. (2002) Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes, 50, 2641-2645.
6. Brownlee, M., Cerami, A., and Vlassara, H. (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318, 1315-1321.
7. Rahbar, S. (2005) The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann. NY. Acad. Sci. USA, 1043, 9-19.
8. Vlassara, H, and Bucala, R. (1996) Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes, 45, S65-66.
9. Soldatos, G., Cooper, M.E. (2006) Advanced glycation end products and vascular structure and function. Curr. Hypertens. Res., 8, 472-478.
10. Schmidt, A.M., and Stern, D. (2000) Atherosclerosis and diabetes: the RAGE connection. Curr. Atheroscler. Rep., 2, 430-436.
11. Yamagishi, S., and Imaizumi T. (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des., 11, 2279-2299.
12. Yamagishi, S., Nakamura, K., Matsui, T., Takenaka, K., Jinnouchi, Y., and Imaizumi, T. (2006) Cardiovascular disease in diabetes. Mini Rev. Med. Chem., 6, 313-318.
13. Victor, V.M., and Rocha, M. (2007) Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr. Pharm. Des., 13, 845-863.
14. Sudano, I., Spieker, L.E., Hermann, F., Flammer, A., Corti, R., Noll, G., and Luscher, T.F. (2007) Protection of endothelial function: targets for nutritional and pharmacological interventions. J. Cardiovasc. Pharmacol., 47, S136-150.
15. Yamagishi, S., Nakamura, K., Matsui, T., Ueda, S., and Imaizumi, T. (2007) Role of postprandial hyperglycaemia in cardiovascular disease in diabetes. Int. J. Clin. Pract., 61, 83-87.
16. Yamagishi, S., Nakamura, K., Matsui, T., Inagaki, Y., Takenaka, K., Jinnouchi, Y., Yoshida, Y., Matsuura, T., Narama, I., Motomiya, Y., Takeuchi, M., Inoue, H., Yoshimura, A., Bucala, R., and Imaizumi, T. (2006) Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem., 281, 20213-20220.
17. Yamagishi, S., Matsui, T., Nakamura, K., Yoshida, T., Takeuchi, M., Inoue, H., Yoshida, Y., and Imaizumi, T. (2007) Pigment-epithelium- derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res., 39, 92-97.
18. Yamagishi, S., Inagaki, Y., Amano, S., Okamoto, T., Takeuchi, M., and Makita, Z. (2002) Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun., 296, 877-882.
19. Yoshida, T., Yamagishi, S., Nakamura, K., Matsui, T., Imaizumi, T., Takeuchi, M., Ueno, T., and Sata, M. (2006) Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett., 580, 2788-2796.
20. Yamagishi, S., Matsui, T., Nakamura, K., and Takeuchi, M. (2005) Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int. J. Tissue React., 27, 185-195.
21. Yamagishi, S., Edelstein, D., Du, X.L., Kaneda, Y., Guzmán, M., and Brownlee, M. (2001) Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J. Biol. Chem., 276, 25096-25100.
22. Yamagishi, S., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., Takeuchi, M., and Makita, Z. (2002) Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem., 277, 20309-20315.
23. Anderson, H.D., Rahmutula, D., and Gardner, D.G. (2004) Tumor necrosis factor-α inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J. Biol. Chem., 279, 963-969.
24. Pacher, P., and Szabo, C. (2006) Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr. Opin. Pharmacol., 6, 136-141.
25. Yamagishi, S., Inagaki, Y., Nakamura, K., Abe, R., Shimizu, T., Yoshimura, A., and Imaizumi, T. (2004) Pigement epithelium-derived factor inhibits TNF-a-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J. Mol. Cell. Cardiol., 37, 497-506.
26. Yamagishi, S., Nakamura, K., Ueda, S., Kato, S., and Imaizumi, T. (2005) Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res., 320, 437-445.